BioCryst Pharmaceuticals Inc (BCRX): Cash & Equivalents
$89.74M
As of 2025-12-31
$154.97M
As of 2026-06-30
-33.5%
3-year compound annual growth
-19.9%
5-year compound annual growth
+12.0%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $89.74M | -14.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $104.71M | -5.4% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $110.64M | -63.7% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $304.77M | -39.6% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $504.39M | +85.4% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $272.13M | +138.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $114.17M | +327.1% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $26.73M | -46.8% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $50.28M | +127.5% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $22.10M | -23.5% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $28.90M | -47.0% | 2018-03-12, Balance as of period end |
| 2014-12-31 | $54.54M | +157.7% | 2017-02-27, Balance as of period end |
| 2013-12-31 | $21.16M | +1.3% | 2016-02-26, Balance as of period end |
| 2012-12-31 | $20.89M | +27.0% | 2015-03-02, Balance as of period end |
| 2011-12-31 | $16.44M | +20.7% | 2014-03-10, Balance as of period end |
| 2010-12-31 | $13.62M | -66.9% | 2013-03-11, Balance as of period end |
| 2009-12-31 | $41.12M | n/a | 2012-03-06, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $87.63M | -15.0% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $183.64M | +93.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $467.71M | +2.6% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $2.60B | +34.7% |
Compare BCRX, RGEN, NVAX, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗